Very thorough.
Not only applied a live-dead like PCR looking at sgRNA, they also cultured the virus and looked for immune histochemistry confirmation of proteins.
Not in the reproductive tissues for the virus.
LNPs from the Vax localize to the ovaries.
Replicative virus 3 months after infection.
And yes.
One patients duration of illness was 230 days.
Just block the clown on this thread trying to claim this is an RNA measurement from a tissue that’s been dead for 230 days.
Very low signal/noise from that account.
A few folks have asked about the vax status.
They would need a Vax specific PCR process to pick that up due to the codon optimizations that were done on the Vax.
These folks found it 5/15/28 days in the plasma.
And if want to learn more about codon optimizations..
Shameless plug of our Preprint.
Great chat with @jjcouey
I have some errors to confess to as I spoke to fast.
1)I was enrolled in a PhD program at UW but dropped out to focus on my job when the HGP starting racing with Craig Venter. So No PhD.
3)The vaccines have N1-Methyl Pseudouridine and I shouldn't shorthand this to Pseudouridine as the former has less wobble than the latter. N1-Methyl does alter the Tm and increase base stacking in RNA but its methyl group steals one potential H-bond.
Let’s have a look at the methods section of the paper.
2 rounds of 45 cycles of PCR?
This is what you do if you want to make polymerase slippage errors near GC rich triplet repeats.
People this library illiterate shouldn’t have the keys to $20K NovaSeq runs.
Having engineered very accurate sequencers, to address PCR polymerase error, you must utilize DNA barcodes that get attached to your PCR products in the first cycle of PCR. Any barcode that over amplifies through the PCR process is discounted.
While I suspect omicron is a directed evolution lab experiment that leaked….
We now have the added complexity of there being patients that have both C19 and the pseudouridine based mRNAs.
Do these recombine/strand switch?
Lots of degenerate bases = more noise in spike.